Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

TLSATiziana Life Sciences LTDSigning up patients

Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Non-Active Secondary Progressive Multiple Sclerosis

0Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

No warning signs right now. That's why the score is 0.

Score over time

Stage
Phase 2
Patients
55 (planned)
Started
Mar 4, 2025
Main results expected
Apr 30, 2026
Fully finished
Aug 30, 2026
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Safety and Tolerability

    Measured over: Day 1 vs Day 169 (end of study)

  • Change in Baseline

    Measured over: Day 1 vs Day 169 (or termination)

  • Safety and Tolerability

    Measured over: Day 1 vs Day 169 (or termination)

  • Safety and Tolerability

    Measured over: Day 1 vs Day 169 (or termination)]

  • Safety and Tolerability

    Measured over: Day 1 vs Day 169 (or termination)

  • Safety and Tolerability

    Measured over: Day 1 vs Day 169 (or termination)

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • none

Raw record changes

  • none yet

Trial ID NCT06890923 · record last updated 2025-06-06 · checked 2026-11-09 15:36 UTC

See the official record on ClinicalTrials.gov (NCT06890923) ↗